Stock Scorer

Purple Biotech (PPBT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Annual

0 350K 700K 1.1M FY17: 100K FY18: 1M FY19: 1M FY20: 1M FY17 FY18 FY19 FY20

Operating Income Annual

0 10M 20M 30M FY21: 17.9M FY22: 22.6M FY23: 22.3M FY24: 11M FY25: 27.5M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-30M -20M -10M 0 10M 20M 30M FY21: 18.5M FY22: -21.8M FY23: -20M FY24: -7.3M FY25: -26.5M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY21: -374K FY22: -16.7M FY23: -19.9M FY24: -14.4M FY25: -5.7M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY20: 1.5M FY21: -489K FY22: -16.8M FY23: -19.9M FY25: -5.7M FY20 FY21 FY22 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 6M 12M 18M FY21: 17.6M FY22: 904.1K FY23: 1.1M FY24: 1.6M FY25: 480.1K FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS Annual

0.00 9.00 18.00 27.00 FY22: 23.97 FY23: 17.96 FY24: 4.99 FY25: 0.03 FY22 FY23 FY24 FY25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for PPBT: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.